MA35459B1 - Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit - Google Patents

Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Info

Publication number
MA35459B1
MA35459B1 MA36863A MA36863A MA35459B1 MA 35459 B1 MA35459 B1 MA 35459B1 MA 36863 A MA36863 A MA 36863A MA 36863 A MA36863 A MA 36863A MA 35459 B1 MA35459 B1 MA 35459B1
Authority
MA
Morocco
Prior art keywords
compounds
compositions
kinase inhibitors
kit
kit kinase
Prior art date
Application number
MA36863A
Other languages
English (en)
Inventor
Vince Yeh
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Bao Nguyen
Hank Michael James Petrassi
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA35459B1 publication Critical patent/MA35459B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (i) et (ii) et des compositions pharmaceutiques en contenant, pouvant être utilisés en tant qu'inhibiteurs des protéines kinases, ainsi que des méthodes d'utilisation desdits composés à des fins de traitement, d'amélioration ou de prévention d'une affection associée à une activité anormale ou dérégulée des kinases. Dans certains modes de réalisation, l'invention concerne des méthodes d'utilisation desdits composés à des fins de traitement, d'amélioration ou de prévention des maladies ou affections impliquant une activation anormale des kinases c-kit ou c-kit et pdgfr (pdgfr±, pdgfr²).
MA36863A 2011-09-01 2014-03-28 Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit MA35459B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
PCT/US2012/052621 WO2013033070A1 (fr) 2011-09-01 2012-08-28 Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Publications (1)

Publication Number Publication Date
MA35459B1 true MA35459B1 (fr) 2014-09-01

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36863A MA35459B1 (fr) 2011-09-01 2014-03-28 Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Country Status (42)

Country Link
US (1) US9199981B2 (fr)
EP (1) EP2751102B1 (fr)
JP (1) JP6117208B2 (fr)
KR (1) KR101959590B1 (fr)
CN (1) CN103764653B (fr)
AP (1) AP2014007494A0 (fr)
AR (1) AR087752A1 (fr)
AU (1) AU2012300248B2 (fr)
BR (1) BR112014004504B1 (fr)
CA (1) CA2845159C (fr)
CL (1) CL2014000494A1 (fr)
CO (1) CO6900140A2 (fr)
CR (1) CR20140106A (fr)
CU (1) CU20140023A7 (fr)
CY (1) CY1121695T1 (fr)
DK (1) DK2751102T3 (fr)
EA (1) EA024293B1 (fr)
ES (1) ES2732671T3 (fr)
GT (1) GT201400036A (fr)
HR (1) HRP20191140T1 (fr)
HU (1) HUE044373T2 (fr)
IL (1) IL231226A (fr)
JO (1) JOP20120246B1 (fr)
LT (1) LT2751102T (fr)
MA (1) MA35459B1 (fr)
ME (1) ME03395B (fr)
MX (1) MX342329B (fr)
MY (1) MY167245A (fr)
PE (1) PE20141033A1 (fr)
PH (1) PH12014500351B1 (fr)
PL (1) PL2751102T3 (fr)
PT (1) PT2751102T (fr)
RS (1) RS59025B1 (fr)
SG (1) SG2014011050A (fr)
SI (1) SI2751102T1 (fr)
TN (1) TN2014000061A1 (fr)
TR (1) TR201909189T4 (fr)
TW (1) TWI543981B (fr)
UA (1) UA110841C2 (fr)
UY (1) UY34300A (fr)
WO (1) WO2013033070A1 (fr)
ZA (1) ZA201401113B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2689429T3 (es) * 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
WO2014110200A1 (fr) 2013-01-10 2014-07-17 Zisman Lawrence S Inhibiteurs de kinase non sélectifs
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
WO2015082411A1 (fr) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-3-carboxamides aryl et hétéroaryl substitués et leur utilisation
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3472152A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques utilisés en tant qu'agents antibacteriens
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
TW202108581A (zh) * 2019-05-13 2021-03-01 瑞士商諾華公司 N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
CN114423758B (zh) 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
TW202237096A (zh) 2020-11-19 2022-10-01 瑞士商諾華公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
WO2022182982A1 (fr) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Méthodes de traitement de maladies et de troubles médiés par la kinase c-kit à l'aide d'un inhibiteur sélectif de kinase c-kit
WO2022194803A1 (fr) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Composés antibactériens
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (fr) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Composes antibacteriens
CA3234515A1 (fr) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Amides d'imidazopyridine et composes apparentes destines a etre utilises dans le traitement d'infections bacteriennes
WO2024089170A1 (fr) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Composés antibactériens
EP4626884A1 (fr) 2022-11-30 2025-10-08 Blueprint Medicines Corporation Dérivés de n-phényl-pyrazolo[1,5-a]pyridine-3-carboxamide utilisés en tant qu'inhibiteurs de kinase c-kit de type sauvage pour le traitement de l'urticaire
EP4630423A1 (fr) * 2022-12-07 2025-10-15 Third Harmonic Bio, Inc. Composés et compositions utilisés en tant qu'inhibiteurs de c-kit kinase
WO2024124002A1 (fr) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Composés et compositions utilisés en tant qu'inhibiteurs de la kinase c-kit
WO2024223859A1 (fr) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Composés antibactériens
US20250042898A1 (en) * 2023-07-25 2025-02-06 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
CN122580315A (zh) * 2024-01-04 2026-08-14 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用
TW202613113A (zh) * 2024-06-11 2026-04-01 大陸商上海翰森生物醫藥科技有限公司 吡唑類衍生物抑制劑、其製備方法和應用
WO2025259929A1 (fr) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Composés et compositions utilisés en tant qu'inhibiteurs de kinase c-kit
WO2025256609A1 (fr) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Formes cristallines d'un inhibiteur sélectif de kinase c-kit
WO2025261494A1 (fr) * 2024-06-21 2025-12-26 上海美悦生物科技发展有限公司 Composé hétérocyclique fusionné, son procédé de préparation et son utilisation
WO2026026755A1 (fr) * 2024-07-30 2026-02-05 上海美悦生物科技发展有限公司 Composé hétérocyclique, son procédé de préparation et son utilisation
WO2026032333A1 (fr) * 2024-08-06 2026-02-12 上海美悦生物科技发展有限公司 Composé hétérocyclique, son procédé de préparation et son utilisation
WO2026037418A1 (fr) * 2024-08-16 2026-02-19 上海美悦生物科技发展有限公司 Composé hétérocyclique, son procédé de préparation et son utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
WO2004001903A2 (fr) 2002-06-20 2003-12-31 Beacon Looms, Inc. Tricot electriquement conducteur
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
CA2845785A1 (fr) * 2011-09-01 2013-03-07 Irm Llc Composes et compositions pouvant etre utilises en tant qu'inhibiteurs de la kinase c-kit
CN103930424A (zh) * 2011-09-01 2014-07-16 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US8569283B2 (en) * 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors

Also Published As

Publication number Publication date
GT201400036A (es) 2015-06-02
RS59025B1 (sr) 2019-08-30
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
JP6117208B2 (ja) 2017-04-19
LT2751102T (lt) 2019-07-10
BR112014004504A2 (pt) 2017-03-28
ES2732671T3 (es) 2019-11-25
KR101959590B1 (ko) 2019-03-18
SG2014011050A (en) 2014-08-28
WO2013033070A1 (fr) 2013-03-07
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29
SI2751102T1 (sl) 2019-08-30
AR087752A1 (es) 2014-04-16
PL2751102T3 (pl) 2019-09-30
CO6900140A2 (es) 2014-03-20
ZA201401113B (en) 2015-10-28
CL2014000494A1 (es) 2014-09-05
DK2751102T3 (da) 2019-07-01
EA201490540A1 (ru) 2014-06-30
BR112014004504B1 (pt) 2022-03-22
PT2751102T (pt) 2019-07-10
PH12014500351B1 (en) 2019-04-03
AU2012300248B2 (en) 2015-08-27
MX342329B (es) 2016-09-26
US20130059846A1 (en) 2013-03-07
TWI543981B (zh) 2016-08-01
IL231226A (en) 2017-03-30
NZ621092A (en) 2016-06-24
US9199981B2 (en) 2015-12-01
CR20140106A (es) 2014-05-02
CN103764653B (zh) 2015-12-02
TR201909189T4 (tr) 2019-07-22
CN103764653A (zh) 2014-04-30
JOP20120246B1 (ar) 2022-03-14
PE20141033A1 (es) 2014-08-30
HUE044373T2 (hu) 2019-10-28
ME03395B (fr) 2020-01-20
MY167245A (en) 2018-08-14
TW201313716A (zh) 2013-04-01
CU20140023A7 (es) 2014-04-24
UA110841C2 (uk) 2016-02-25
CA2845159C (fr) 2020-11-03
CY1121695T1 (el) 2020-07-31
UY34300A (es) 2013-04-05
CA2845159A1 (fr) 2013-03-07
EP2751102B1 (fr) 2019-03-27
AP2014007494A0 (en) 2014-03-31
AU2012300248A1 (en) 2014-04-17
PH12014500351A1 (en) 2014-04-07
EA024293B1 (ru) 2016-09-30
MX2014002482A (es) 2014-11-25
IL231226A0 (en) 2014-04-30
EP2751102A1 (fr) 2014-07-09

Similar Documents

Publication Publication Date Title
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA38483A1 (fr) Inhibiteurs de l'ido
MA40290A1 (fr) Agents immunorégulateurs
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA34474B1 (fr) Agonistes de gpr40
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA35576B1 (fr) Nouveaux composés
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA44948A1 (fr) Inhibiteurs de bace 1
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38346B1 (fr) 2,3-benzodiazépines bicyclo- et spirocyclosubstituées
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr